Neonc Technologies (NASDAQ:NTHI) Trading Down 0.1% – Should You Sell?

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) dropped 0.1% during trading on Wednesday . The stock traded as low as $9.30 and last traded at $9.41. Approximately 13,768 shares traded hands during trading, a decline of 76% from the average daily volume of 56,570 shares. The stock had previously closed at $9.42.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Zacks Research upgraded Neonc Technologies to a “hold” rating in a report on Wednesday, January 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Neonc Technologies in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Neonc Technologies currently has a consensus rating of “Reduce”.

Neonc Technologies Trading Down 0.1%

The firm’s 50-day moving average price is $9.43 and its 200 day moving average price is $9.33.

Hedge Funds Weigh In On Neonc Technologies

A number of hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC raised its stake in shares of Neonc Technologies by 5,314.8% in the fourth quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after purchasing an additional 8,982 shares during the last quarter. Foundations Investment Advisors LLC bought a new position in shares of Neonc Technologies in the third quarter valued at approximately $100,000. SLT Holdings LLC purchased a new position in shares of Neonc Technologies during the third quarter valued at approximately $100,000. Goldman Sachs Group Inc. bought a new stake in Neonc Technologies during the fourth quarter worth $124,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Neonc Technologies during the fourth quarter worth $126,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.